Fintel reports that on December 3, 2025, Morgan Stanley downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN ...
Morgan Stanley has downgraded Regeneron Pharmaceuticals ( REGN) to equal-weight from overweight saying that the stock is fairly valued. The bank maintained its price target of $767 (~3% upside based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback